Skip to main content
News Hölzel 01.2022
© Roberta Turiello

News categories: Publication

Tumor Cell Plasticity in Therapy Resistance

Prof. Dr. Michael Hölzel, Member of the Cluster of Excellence ImmunoSensation2 at the University of Bonn receives project funding of 1.5 million euros provided by the German Cancer Aid.

Cancer cells can constantly change and in this way evade the immune system. Prof. Dr. Michael Hölzel from the Institute of Experimental Oncology at the University of Bonn is developing an immunotherapy against black skin cancer: He wants to use "smart" immune cells to get a grip on the tumor cells that are currently trying to make themselves invisible. German Cancer Aid is funding the project with 1.5 million euros over the next five years as part of its new "Excellence Funding Program for Established Scientists".

Malignant melanoma (black skin cancer) originates from the pigment-forming melanocytes in the skin. "Melanocytes are very important for us to protect our skin and body from the harmful effects of UV radiation," says Prof. Dr. Michael Hölzel, director of the Institute of Experimental Oncology at the University Hospital Bonn. "One characteristic of melanoma is that it tends to metastasize to different sites inside the body early on." Additionally, melanoma cells are able to evade detection and hence elimination by T Cells by changing their molecular appearance. A key goal of Hölzel’s research is to understand the molecular mechanisms that orchestrate tumor cell plasticity. "For many years, together with other research teams, we have been investigating which influences change the appearance of melanoma cells - these include, for example, inflammatory signals in the tumor tissue," says Hölzel.

Cancer cells also change during the course of immunotherapy and evade the immune system. In the project funded by the German Cancer Aid, Hölzel wants to adjust the immunotherapy accordingly, so that its effectiveness lasts longer. Further, the scientist wants to investigate the phenomenon of various differing melanoma cells arising spontaneously, exhibiting a plethora of different surface features. "In the project, we are looking into the question of whether pure chance also plays a role in this - as if the dice decides which characteristics a melanoma cell has," says the Hölzel. If this is the case, how does such molecular dicing work? How may new therapies like tumor vaccines be made less vulnerable to the power of chance?

In recent years, there has been progress in trying to make the immune system "sharp" against black skin cancer tumor cells. "But only a portion of patients benefit, and the disease often comes back," Hölzel says. "This means there is a great need for better therapies that are smarter than the tumor, so to speak."

Michael Hölzel is a member of the Cluster of Excellence "ImmunoSensation2" and the Transdisciplinary Research Units "Mathematics, Modeling and Simulation of Complex Systems" and "Life and Health" at the University of Bonn.

As part of its new "Excellence Funding Program for Established Scientists", German Cancer Aid is funding a total of six particularly innovative, but also "daring" projects ('High Risk - High Gain'). "In this way, we would like to give researchers the necessary financial and time freedom to implement trend-setting ideas for the prevention, diagnosis and treatment of cancer and to break new ground conceptually," says Gerd Nettekoven, Chairman of the Board of German Cancer Aid. "We see this as an opportunity for a substantial gain in knowledge and the potential to decisively advance cancer medicine."

Source: Press release of German Cancer Aid


Contact

Prof. Dr. Michael Hölzel

Direktor des Instituts für Experimentelle Onkologie

Universitätsklinikum Bonn

Tel. +49-228-28712170

E-Mail: Michael.Hoelzel@ukbonn.de

Related news

Scientists that contributed to the study

News categories: Publication

New way to prevent duodenal cancer

People with the hereditary disease familial adenomatous polyposis (FAP) have a greatly increased risk of developing a malignant tumor of the duodenum. Researchers at the University Hospital Bonn (UKB) and the Cluster of Excellence ImmunoSensation2 at the University of Bonn have now discovered a mechanism in the local immune system that can drive the development of cancer. They see this as a promising new approach to preventing duodenal carcinoma in people with FAP. The results have now been published in the journal "Nature Communications".
View entry
Kathrin Leppek Publication PM

News categories: Publication

Starting points for the control of protein synthesis

The research field of "cellular IRESes" lay dormant for decades, as there was no uniform standard of reliable methods for the clear characterization of these starting points for the ribosome-mediated control of gene expression. Researchers at the University Hospital Bonn (UKB) and the University of Bonn, in collaboration with Stanford University in California (USA), have now developed a toolbox as a new gold standard for this field. The results of their work have been published in The EMBO Journal.
View entry
Pandyra Publication Graphical Abstract

News categories: Publication

Genetic mutation affects survival after viral infection

Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry

Back to the news overview